Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Palisade Bio (PALI) Acquisitions (2021 - 2022)

Palisade Bio has reported Acquisitions over the past 2 years, most recently at -$3.3 million for Q4 2022.

Quarterly Acquisitions changed N/A to -$3.3 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was -$3.0 million through Dec 2022, changed N/A year-over-year, with the annual reading at $3.3 million for FY2021, N/A changed from the prior year.
Acquisitions was -$3.3 million for Q4 2022 at Palisade Bio, down from $348000.0 in the prior quarter.
Over five years, Acquisitions peaked at $348000.0 in Q3 2021 and troughed at -$3.3 million in Q4 2022.